Business News • PR NewsWire • Castle Biosciences' Non-Invasive Gene Expression Profile Test Shown to Identify Sentinel Lymph Node Negative Melanoma Patients at High Risk of Metastasis

Castle Biosciences' Non-Invasive Gene Expression Profile Test Shown to Identify Sentinel Lymph Node Negative Melanoma Patients at High Risk of Metastasis

Castle Biosciences' Non-Invasive Gene Expression Profile Test Shown to Identify Sentinel Lymph Node Negative Melanoma Patients at High Risk of Metastasis

DENVER, March 22, 2014 /PRNewswire/ -- Castle Biosciences Inc. today announced study results showing its gene expression profile (GEP) test (DecisionDx-Melanoma) can identify primary cutaneous (skin) melanoma tumors that are likely to metastasize in patients who had a negative sentinel...

View More : http://www.prnewswire.com/news-releases/castle-biosciences-non-invasive-gene-expression-profile-test-shown-to-identify-s...

Releted News by prnewswire

CleanEquity Monaco 2014 - Ankündigung weiterer Partnerschaften und Unternehmen

Aquavit Pharmaceuticals Announces Official Launch of AQUAGOLD® fine touch™ at the 72nd Annual Meeting of the American Academy of Dermatology

Sinopec announces 2013 full year results

Sie fragen sich, wie Ihr Unternehmen mit Risiken umgehen, Compliance-Anforderungen erfüllen und nachhaltige Änderungen erzielen kann?

Treffen Sie GlaxoSmithKline, Novartis, Pfizer, Roche und andere zu Gesprächen über Präparate- und Probenmanagement